Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie
-
Biomed. Pharmacother. · Apr 2014
Morphine improved the antitumor effects on MCF-7 cells in combination with 5-Fluorouracil.
The most frequently used opioid in cancer pain management is morphine which remains a cornerstone for the management of cancer pain, due to the largest experience existing among physicians and widely availability in a variety of formulation. Considering that analgesics on cancer pain is often under the condition of chemotherapy and 5-Fluorouracil (5-FU) is widely used today as a potent drug for the treatment of advanced cancers, whether analgesics such as morphine, interferes the chemotherapy such as 5-FU, arose as a considerable problem. ⋯ These results suggest that the morphine may have the beneficial effects on the antitumor chemotherapy with 5-FU, in stead of interferential effects.
-
Biomed. Pharmacother. · Oct 2013
Clinical TrialOral topotecan: Bioavailability, pharmacokinetics and impact of ABCG2 genotyping in Chinese patients with advanced cancers.
Oral topotecan (Hycamtin(®)) has been recently approved for the treatment of relapsed small cell lung cancer (SCLC) in 2007, however, the bioavailability and pharmacokinetic data of topotecan for Chinese patients is still limited. Xinze(®) is a new and the only capsule formulation of topotecan used in China that is similar to Hycamtin(®). The current study aimed to investigate the absolute bioavailability and pharmacokinetics of Xinze(®) in Chinese patients with advanced cancers. ⋯ The patients with heterozygous SNPs had essentially the same bioavailability and pharmacokinetics. The bioavailability of topotecan after oral administration illustrates good systemic exposure at dosages of 1.5 mg/m(2)/d and 1.9 mg/m(2)/d over a five-day schedule in Chinese patients. On a dose-normalized basis, the values of Cmax and AUC0-t for total topotecan in Chinese patients were higher than in Caucasians following oral and intravenous administration, while the T1/2 was consistent.
-
Biomed. Pharmacother. · Jun 2012
Clinical TrialThalidomide for improving cutaneous and pulmonary sarcoidosis in patients resistant or with contraindications to corticosteroids.
Limited data report thalidomide improves cutaneous sarcoidosis; no benefit has been reported for pulmonary localization. ⋯ Thalidomide, long-term at mid-low doses, can be considered as an effective therapeutic alternative in chronic sarcoidosis with resistance or contraindications to steroids.
-
Biomed. Pharmacother. · Jun 2012
The effect of monosialotetrahexosylganglioside (GM1) in prevention of oxaliplatin induced neurotoxicity: a retrospective study.
Oxaliplatin is a key agent in the treatment of colorectal cancer. However, peripheral neuropathy markedly limits the use of oxaliplatin. This retrospective study was performed to assess the efficacy of monosialotetrahexosylganglioside (GM1) for preventing oxaliplatin induced neurotoxicity. ⋯ No difference was detected in objective response rate, progress free survival, and median overall survival between GM1 group and control group. The retrospective study demonstrated that GM1 significantly reduced the incidence of oxaliplatin induced neuropathy, especially severe neuropathy, without impairment of efficacy. Prospective trials of GM1 as neuroprotective of oxaliplatin treatment in colorectal cancer are warranted.
-
Biomed. Pharmacother. · Feb 2012
Propofol reduces MMPs expression by inhibiting NF-κB activity in human MDA-MB-231 cells.
Propofol is a common clinical anesthesia agent which is now widely used in relieving pain of patients with chronic cancer as an adjuvant therapy. In our study, we found another effect of propofol in the therapy of chronic cancer patients. We used the breast cancer cell lines to detect the effects and molecular mechanisms of clinically relevant concentrations of propofol, finding that propofol reduced the level of MMP breast cancer by inhibition of NF-κB pathways, which restrained migration and invasion of breast cancer cells significantly. Our finding provides a new sight into propofol in cancer treatment and, suggesting that propofol not only can be an anesthesia agent which reduces pain but plays a important role of inhibiting the invasion and migration of breast cancer cells in the therapy of chronic breast cancer patients.